Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTRobert Izquierdo, The Motley FoolSat, June 6, 2026 at 8:39 PM GMT+2 4 min readChief Legal Officer Dennis Cho reported the sale of 14,205 shares of Twist Bioscience Corporation (NASDAQ:TWST) on May 29, 2026, for a transaction value of approximately $991,000, according to a SEC Form 4 filing.Transaction summaryMetricValueShares sold (direct)14,205Transaction value$991,000Post-transaction shares (direct)120,094Post-transaction value (direct ownership)$8.03 millionTransaction value based on SEC Form 4 reported price ($69.75); post-transaction value based on holdings as valued using the May 29, 2026 close price.Key questionsHow does the size of this sale compare to Dennis Cho’s historical trading activity?This 14,205-share disposition is the largest single sale executed by Cho in the past two years, nearly 12 times the average sell-only trade size of 1,147 shares across his 54 sell events, and substantially larger than any prior transaction on record.What proportion of Cho’s holdings did this transaction represent, and how does that compare to recent periods?The sale accounted for 10.58% of Cho’s direct holdings at the time, a material step-down from 134,299 to 120,094 shares, and contrasts with the smaller incremental sales that characterized most of his trading since January 2025.What is the context for the sale relative to recent stock performance and capacity?As of the May 29, 2026 transaction date, Twist Bioscience shares had appreciated 131.5% over the prior year, and Cho’s remaining direct holdings now represent approximately 0.19% of outstanding shares, with ongoing selling cadence reflecting both reduced holdings capacity and sustained share price momentum.Company overviewMetricValuePrice (as of market close 2026-05-29)$66.87Market capitalization$4.31 billionRevenue (TTM)$409.48 millionNet income (TTM)($81.28 million)* 1-year performance is calculated using May 29th, 2026 as the reference date.Company snapshotTwist Bioscience offers synthetic DNA products, including genes, sample preparation tools, antibody libraries for drug discovery, and DNA-based data storage solutions.It generates revenue through the sale of synthetic DNA-based products and collaborative research agreements with pharmaceutical and biotechnology partners.The company serves pharmaceutical companies, biotechnology firms, academic research institutions, and organizations involved in diagnostics and drug development.Twist Bioscience Corporation is a leading synthetic biology company specializing in high-throughput DNA synthesis using a proprietary silicon-based platform. The company leverages its technology to provide scalable, cost-effective synthetic DNA products for research, diagnostics, and therapeutic development.Terms and Privacy PolicyPrivacy & Cookie SettingsMore Info